Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): A study on 50 cases

Jerzy Lasota, Agnieszka Wozniak, Janusz Kopczynski, Agnieszka Dansonka-Mieszkowska, Bartek Wasag, Tomoko Mitsuhashi, Marrit Sarlomo-Rikala, Jeffrey R Lee, Regine Schneider-Stock, Jerzy Stachura, Janusz Limon, Markku Miettinen

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Mutational activation of KIT or PDGFRA is considered an early step in pathogenesis of gastrointestinal stromal tumors (GISTs); however, other nonrandom genetic changes have also been identified. At least three common regions of deletions on chromosome 22q, which may harbor putative tumor suppressor genes, have been defined. However, mapping of these regions has been inconsistent. It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region. This study was undertaken to evaluate loss of heterozygosity (LOH) on chromosome 22q in 50 GISTs, including 10 GANTs. Four tumors were incidental minimal lesions ≤ 10 mm in diameter. LOH was evaluated using 20 PCR-based microsatellite markers and capillary gel electrophoresis. In all, 15 (30%) cases showed LOH of more than 75% of informative markers, suggesting loss of chromosome 22q. A total of 24 GISTs (50%) revealed LOH of one to seven informative markers clustered in different loci suggesting simultaneous involvement of different regions. The highest frequency of LOH was seen at D22S922 and D22S425, mapped to 22q13.33 and 22q11.22, respectively. However, LOH at other regions including IL2RB and NF2 locus was also found. No NF2 mutations were identified in four analyzed tumors. LOH on chromosome 22q was more frequent among intestinal than among gastric GISTs; however, there was no difference between LOH pattern seen in tumors defined by different histologic, ultrastructural (GANT) and molecular features (KIT and PDGFRA mutations). Although minimal GISTs revealed LOH on chromosome 22q, there was a higher LOH frequency in malignant than in benign tumors. An isolated LOH at D22S425 was equally found in both benign and malignant tumors. These observations may suggest that LOHs on chromosome 22q in GISTs play a role in early stages of tumor formation as well as in late tumor progression.

Original languageEnglish (US)
Pages (from-to)237-247
Number of pages11
JournalLaboratory Investigation
Volume85
Issue number2
DOIs
StatePublished - Feb 1 2005

Fingerprint

Gastrointestinal Stromal Tumors
Loss of Heterozygosity
Chromosomes
Neoplasms
Autonomic Pathways
Chromosome Deletion
Mutation
Capillary Electrophoresis
Tumor Suppressor Genes
Cytogenetics
Microsatellite Repeats
Stomach
Gels

Keywords

  • Chromosome 22
  • GIST
  • LOH

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology

Cite this

Lasota, J., Wozniak, A., Kopczynski, J., Dansonka-Mieszkowska, A., Wasag, B., Mitsuhashi, T., ... Miettinen, M. (2005). Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): A study on 50 cases. Laboratory Investigation, 85(2), 237-247. https://doi.org/10.1038/labinvest.3700218

Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs) : A study on 50 cases. / Lasota, Jerzy; Wozniak, Agnieszka; Kopczynski, Janusz; Dansonka-Mieszkowska, Agnieszka; Wasag, Bartek; Mitsuhashi, Tomoko; Sarlomo-Rikala, Marrit; Lee, Jeffrey R; Schneider-Stock, Regine; Stachura, Jerzy; Limon, Janusz; Miettinen, Markku.

In: Laboratory Investigation, Vol. 85, No. 2, 01.02.2005, p. 237-247.

Research output: Contribution to journalArticle

Lasota, J, Wozniak, A, Kopczynski, J, Dansonka-Mieszkowska, A, Wasag, B, Mitsuhashi, T, Sarlomo-Rikala, M, Lee, JR, Schneider-Stock, R, Stachura, J, Limon, J & Miettinen, M 2005, 'Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): A study on 50 cases', Laboratory Investigation, vol. 85, no. 2, pp. 237-247. https://doi.org/10.1038/labinvest.3700218
Lasota J, Wozniak A, Kopczynski J, Dansonka-Mieszkowska A, Wasag B, Mitsuhashi T et al. Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): A study on 50 cases. Laboratory Investigation. 2005 Feb 1;85(2):237-247. https://doi.org/10.1038/labinvest.3700218
Lasota, Jerzy ; Wozniak, Agnieszka ; Kopczynski, Janusz ; Dansonka-Mieszkowska, Agnieszka ; Wasag, Bartek ; Mitsuhashi, Tomoko ; Sarlomo-Rikala, Marrit ; Lee, Jeffrey R ; Schneider-Stock, Regine ; Stachura, Jerzy ; Limon, Janusz ; Miettinen, Markku. / Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs) : A study on 50 cases. In: Laboratory Investigation. 2005 ; Vol. 85, No. 2. pp. 237-247.
@article{59e37a073f8b43eeab56399f29dd9d51,
title = "Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): A study on 50 cases",
abstract = "Mutational activation of KIT or PDGFRA is considered an early step in pathogenesis of gastrointestinal stromal tumors (GISTs); however, other nonrandom genetic changes have also been identified. At least three common regions of deletions on chromosome 22q, which may harbor putative tumor suppressor genes, have been defined. However, mapping of these regions has been inconsistent. It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region. This study was undertaken to evaluate loss of heterozygosity (LOH) on chromosome 22q in 50 GISTs, including 10 GANTs. Four tumors were incidental minimal lesions ≤ 10 mm in diameter. LOH was evaluated using 20 PCR-based microsatellite markers and capillary gel electrophoresis. In all, 15 (30{\%}) cases showed LOH of more than 75{\%} of informative markers, suggesting loss of chromosome 22q. A total of 24 GISTs (50{\%}) revealed LOH of one to seven informative markers clustered in different loci suggesting simultaneous involvement of different regions. The highest frequency of LOH was seen at D22S922 and D22S425, mapped to 22q13.33 and 22q11.22, respectively. However, LOH at other regions including IL2RB and NF2 locus was also found. No NF2 mutations were identified in four analyzed tumors. LOH on chromosome 22q was more frequent among intestinal than among gastric GISTs; however, there was no difference between LOH pattern seen in tumors defined by different histologic, ultrastructural (GANT) and molecular features (KIT and PDGFRA mutations). Although minimal GISTs revealed LOH on chromosome 22q, there was a higher LOH frequency in malignant than in benign tumors. An isolated LOH at D22S425 was equally found in both benign and malignant tumors. These observations may suggest that LOHs on chromosome 22q in GISTs play a role in early stages of tumor formation as well as in late tumor progression.",
keywords = "Chromosome 22, GIST, LOH",
author = "Jerzy Lasota and Agnieszka Wozniak and Janusz Kopczynski and Agnieszka Dansonka-Mieszkowska and Bartek Wasag and Tomoko Mitsuhashi and Marrit Sarlomo-Rikala and Lee, {Jeffrey R} and Regine Schneider-Stock and Jerzy Stachura and Janusz Limon and Markku Miettinen",
year = "2005",
month = "2",
day = "1",
doi = "10.1038/labinvest.3700218",
language = "English (US)",
volume = "85",
pages = "237--247",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs)

T2 - A study on 50 cases

AU - Lasota, Jerzy

AU - Wozniak, Agnieszka

AU - Kopczynski, Janusz

AU - Dansonka-Mieszkowska, Agnieszka

AU - Wasag, Bartek

AU - Mitsuhashi, Tomoko

AU - Sarlomo-Rikala, Marrit

AU - Lee, Jeffrey R

AU - Schneider-Stock, Regine

AU - Stachura, Jerzy

AU - Limon, Janusz

AU - Miettinen, Markku

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Mutational activation of KIT or PDGFRA is considered an early step in pathogenesis of gastrointestinal stromal tumors (GISTs); however, other nonrandom genetic changes have also been identified. At least three common regions of deletions on chromosome 22q, which may harbor putative tumor suppressor genes, have been defined. However, mapping of these regions has been inconsistent. It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region. This study was undertaken to evaluate loss of heterozygosity (LOH) on chromosome 22q in 50 GISTs, including 10 GANTs. Four tumors were incidental minimal lesions ≤ 10 mm in diameter. LOH was evaluated using 20 PCR-based microsatellite markers and capillary gel electrophoresis. In all, 15 (30%) cases showed LOH of more than 75% of informative markers, suggesting loss of chromosome 22q. A total of 24 GISTs (50%) revealed LOH of one to seven informative markers clustered in different loci suggesting simultaneous involvement of different regions. The highest frequency of LOH was seen at D22S922 and D22S425, mapped to 22q13.33 and 22q11.22, respectively. However, LOH at other regions including IL2RB and NF2 locus was also found. No NF2 mutations were identified in four analyzed tumors. LOH on chromosome 22q was more frequent among intestinal than among gastric GISTs; however, there was no difference between LOH pattern seen in tumors defined by different histologic, ultrastructural (GANT) and molecular features (KIT and PDGFRA mutations). Although minimal GISTs revealed LOH on chromosome 22q, there was a higher LOH frequency in malignant than in benign tumors. An isolated LOH at D22S425 was equally found in both benign and malignant tumors. These observations may suggest that LOHs on chromosome 22q in GISTs play a role in early stages of tumor formation as well as in late tumor progression.

AB - Mutational activation of KIT or PDGFRA is considered an early step in pathogenesis of gastrointestinal stromal tumors (GISTs); however, other nonrandom genetic changes have also been identified. At least three common regions of deletions on chromosome 22q, which may harbor putative tumor suppressor genes, have been defined. However, mapping of these regions has been inconsistent. It has also been speculated that GI autonomous nerve tumors (GANTs), GISTs with ultrastructural features suggestive of autonomic nerve differentiation, are characterized by a specific deletion involving 22q13 cytogenetic region. This study was undertaken to evaluate loss of heterozygosity (LOH) on chromosome 22q in 50 GISTs, including 10 GANTs. Four tumors were incidental minimal lesions ≤ 10 mm in diameter. LOH was evaluated using 20 PCR-based microsatellite markers and capillary gel electrophoresis. In all, 15 (30%) cases showed LOH of more than 75% of informative markers, suggesting loss of chromosome 22q. A total of 24 GISTs (50%) revealed LOH of one to seven informative markers clustered in different loci suggesting simultaneous involvement of different regions. The highest frequency of LOH was seen at D22S922 and D22S425, mapped to 22q13.33 and 22q11.22, respectively. However, LOH at other regions including IL2RB and NF2 locus was also found. No NF2 mutations were identified in four analyzed tumors. LOH on chromosome 22q was more frequent among intestinal than among gastric GISTs; however, there was no difference between LOH pattern seen in tumors defined by different histologic, ultrastructural (GANT) and molecular features (KIT and PDGFRA mutations). Although minimal GISTs revealed LOH on chromosome 22q, there was a higher LOH frequency in malignant than in benign tumors. An isolated LOH at D22S425 was equally found in both benign and malignant tumors. These observations may suggest that LOHs on chromosome 22q in GISTs play a role in early stages of tumor formation as well as in late tumor progression.

KW - Chromosome 22

KW - GIST

KW - LOH

UR - http://www.scopus.com/inward/record.url?scp=13444282071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444282071&partnerID=8YFLogxK

U2 - 10.1038/labinvest.3700218

DO - 10.1038/labinvest.3700218

M3 - Article

C2 - 15580284

AN - SCOPUS:13444282071

VL - 85

SP - 237

EP - 247

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 2

ER -